Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Alexza Pharmaceutica (ALXA) OTHER OTC

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 20,340
  • Shares Outstanding, K 21,750
  • Annual Sales, $ 5,030 K
  • Annual Income, $ -21,310 K
  • 36-Month Beta 0.75
  • Price/Sales 4.05
  • Price/Book 0.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.81
  • Most Recent Earnings N/A on N/A
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9020 +10.86%
on 06/17/16
1.0300 -2.91%
on 05/25/16
+0.0800 (+8.70%)
since 05/20/16
3-Month
0.4300 +132.56%
on 04/05/16
1.0300 -2.91%
on 05/25/16
+0.4400 (+78.57%)
since 03/21/16
52-Week
0.2200 +354.55%
on 02/09/16
1.6000 -37.50%
on 09/25/15
-0.2600 (-20.63%)
since 06/19/15

Most Recent Stories

More News
Alexza Announces U.S. Approval of ADASUVE® sNDA

Alexza Pharmaceuticals, Inc., a wholly-owned subsidiary of Ferrer Therapeutics, Inc., today announced that its supplemental New Drug Application (sNDA) seeking certain changes in the product label and...

Hercules Announces Strong Second Quarter Financial Results with $0.32 NII per Share and a $0.31 Quarterly Dividend

--Q2 2016 Financial Highlights

Alexza Pharmaceuticals Acquired by Ferrer

Alexza Pharmaceuticals, Inc. (OTC: ALXA, "Alexza") and Grupo Ferrer Internacional, S.A. ("Ferrer") today announced the expiration of the tender offer (the "Offer") by Ferrer Pharma Inc., a wholly-owned...

Parkinson's Disease Market - Pipeline Review, H2 2015 - 150+ Companies and Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/6b8nmd/parkinsons) has announced the addition of the "Parkinson's Disease - Pipeline Review, H2 2015" report to their offering. This report...

Global Insomnia Therapeutic Development Pipeline Review, H2 2015

Research and Markets (http://www.researchandmarkets.com/research/65tkn8/insomnia) has announced the addition of the "Insomnia - Pipeline Review, H2 2015" report to their offering. This report provides...

New Strong Buy Stocks for December 31st

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Thursday

New Strong Buy Stocks for December 29th

Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Tuesday

Alexza Pharmaceuticals Announces Receipt of NASDAQ Staff Determination; Alexza to Request Hearing with NASDAQ Listing Qualifications Panel

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that on December 17, 2015, the Company received a letter from the Nasdaq Staff indicating that the Company had not regained compliance with the...

4 Stocks to Watch Trading Under $500M Market Cap

NEW YORK, NY / ACCESSWIRE / December 22, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are...

Alexza Pharmaceuticals Announces Interim Results from its Phase 2a Study of AZ-002 (Staccato® alprazolam) in Epilepsy Patients

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced interim results of its Phase 2a study of AZ-002 (Staccato® alprazolam) in epilepsy patients. AZ-002 produced a dose-related decrease in mean...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Buy with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Strong. Long term indicators fully support a continuation of the trend.

See More

Support & Resistance

2nd Resistance Point 1.0000
1st Resistance Point 1.0000
Last Price 1.0000
1st Support Level 1.0000
2nd Support Level 1.0000

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.